IMMUNIC, INC. 8-K

What Happened

• On June 29, 2026 Immunic, Inc. (IMUX) held its annual meeting of stockholders and filed an 8-K reporting the results. Stockholders elected Michael Bonney, Thorvald Nagel and Dr. Richard Rudick as Class III directors (terms through the 2029 annual meeting).
• Shareholders approved an amendment to the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance by 6,000,000 to a total of 8,644,887 shares. Stockholders also ratified Baker Tilly US, LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Meeting date: June 29, 2026. Quorum: 8,885,263 shares present of 13,621,483 shares entitled to vote.
• Director election vote totals (FOR / WITHHELD / broker non-votes):
  • Michael Bonney: 5,692,503 / 85,660 / 3,107,100
  • Thorvald Nagel: 5,064,713 / 713,450 / 3,107,100
  • Dr. Richard Rudick: 5,688,265 / 89,898 / 3,107,100
• Equity plan amendment vote: FOR 4,391,782 / AGAINST 1,361,843 / ABSTAIN 24,538 / BROKER NON-VOTES 3,107,100 — amendment approved.
• Auditor ratification vote: FOR 8,566,232 / AGAINST 249,436 / ABSTAIN 69,595 — Baker Tilly ratified.

Why It Matters

• The approved 6,000,000-share increase to the equity incentive plan expands the pool for employee, director and consultant awards, which can support hiring and retention but may increase potential dilution for current shareholders.
• Re-election of the three Class III directors maintains board continuity through 2029.
• Ratification of Baker Tilly confirms the company’s auditor for fiscal 2026, which is a routine governance item important for financial reporting and audit continuity.